{"filing":{"accession_number":"0001367644-26-000068","cik":"0001367644","ticker":"EBS","company_name":"Emergent BioSolutions Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ebs-20260626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000068/ebs-20260626.htm"},"events":[{"id":14546,"run_id":12957,"accession_number":"0001367644-26-000068","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Emergent BioSolutions announced a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services for supply of ACAM2000® vaccine under an existing 10-year government contract, representing a material operational and revenue milestone.","company_name":"Emergent BioSolutions Inc.","ticker":"EBS","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12018,"accession_number":"0001367644-26-000068","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This is a contract modification exercising an option year under an existing 10-year government contract, valued at $52.7 million. While it creates a direct financial obligation for Emergent to deliver vaccine doses, it is fundamentally a revenue-generating contract award, not a debt issuance. The event is material to investors as a significant government contract, but does not fit the debt_issuance category which is intended for creation of new financial obligations (debt, notes, bonds, credit facilities). This should be classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T15:15:41.065374+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12019,"accession_number":"0001367644-26-000068","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Emergent BioSolutions announced a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services for supply of ACAM2000® vaccine. This is a material government contract award that affects the company's revenue and operational capacity, but does not fit the specific categories of debt issuance, M\u0026A activity, or other named financial events. The disclosure centers on a significant commercial/operational milestone—a substantial contract modification under an existing 10-year government contract—making it an operational event rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T15:15:41.065374+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12018,"accession_number":"0001367644-26-000068","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.15,"reasoning":"This is a contract modification exercising an option year under an existing 10-year government contract, valued at $52.7 million. While it creates a direct financial obligation for Emergent to deliver vaccine doses, it is fundamentally a revenue-generating contract award, not a debt issuance. The event is material to investors as a significant government contract, but does not fit the debt_issuance category which is intended for creation of new financial obligations (debt, notes, bonds, credit facilities). This should be classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T15:15:41.065374+00:00","company_name":"Emergent BioSolutions Inc.","ticker":"EBS","filing_date":"2026-06-29"},{"id":12019,"accession_number":"0001367644-26-000068","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Emergent BioSolutions announced a contract modification valued at $52.7 million from the U.S. Department of Health and Human Services for supply of ACAM2000® vaccine. This is a material government contract award that affects the company's revenue and operational capacity, but does not fit the specific categories of debt issuance, M\u0026A activity, or other named financial events. The disclosure centers on a significant commercial/operational milestone—a substantial contract modification under an existing 10-year government contract—making it an operational event rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T15:15:41.065374+00:00","company_name":"Emergent BioSolutions Inc.","ticker":"EBS","filing_date":"2026-06-29"}]}